InDex Pharmaceuticals Holding AB
STO:FLERIE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.8
55.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
InDex Pharmaceuticals Holding AB
Total Liabilities & Equity
InDex Pharmaceuticals Holding AB
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Total Liabilities & Equity
kr4.3B
|
CAGR 3-Years
109%
|
CAGR 5-Years
105%
|
CAGR 10-Years
N/A
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Total Liabilities & Equity
kr1.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
Total Liabilities & Equity
kr3.6B
|
CAGR 3-Years
51%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Total Liabilities & Equity
kr10B
|
CAGR 3-Years
56%
|
CAGR 5-Years
136%
|
CAGR 10-Years
N/A
|
|
|
IRLAB Therapeutics AB
STO:IRLAB A
|
Total Liabilities & Equity
kr177.1m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
Total Liabilities & Equity
kr634.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
InDex Pharmaceuticals Holding AB
Glance View
InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.
See Also
What is InDex Pharmaceuticals Holding AB's Total Liabilities & Equity?
Total Liabilities & Equity
4.3B
SEK
Based on the financial report for Sep 30, 2024, InDex Pharmaceuticals Holding AB's Total Liabilities & Equity amounts to 4.3B SEK.
What is InDex Pharmaceuticals Holding AB's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
105%
Over the last year, the Total Liabilities & Equity growth was 1 002%. The average annual Total Liabilities & Equity growth rates for InDex Pharmaceuticals Holding AB have been 109% over the past three years , 105% over the past five years .
You don't have any saved screeners yet
